Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06265727

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Led by Corbus Pharmaceuticals Inc. · Updated on 2026-01-08

348

Participants Needed

41

Research Sites

147 weeks

Total Duration

On this page

Sponsors

C

Corbus Pharmaceuticals Inc.

Lead Sponsor

C

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.

CONDITIONS

Official Title

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed after all appropriate therapies or have no standard therapy with proven benefit
  • For Part C, HNSCC participants may enroll as first-line therapy
Not Eligible

You will not qualify if you...

  • Active or uncontrolled CNS metastases
  • History of solid tumors other than the diseases under study
  • History of and/or current cardiovascular events or conditions in the previous 6 months
  • Pre-existing Grade 2 or higher neuropathy
  • Hemoglobin A1C 8% or higher, uncontrolled diabetes mellitus, or known diabetic neuropathy
  • Active ocular disease at baseline
  • Chronic severe liver disease or liver cirrhosis
  • Interstitial lung disease or pneumonitis within 6 months before starting treatment
  • Other significant comorbidities

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 41 locations

1

O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham

Birmingham, Alabama, United States, 35294

Actively Recruiting

2

City of Hope Cancer Center

Duarte, California, United States, 91010

Actively Recruiting

3

Moores Cancer Centre at UC San Diego Health

San Diego, California, United States, 92037

Actively Recruiting

4

Helen Diller Family Comprehensive Cancer Center - UCSF

San Francisco, California, United States, 94115

Actively Recruiting

5

Rocky Mountain Cancer Centres

Denver, Colorado, United States, 80218

Active, Not Recruiting

6

Yale Cancer Center

New Haven, Connecticut, United States, 06510

Actively Recruiting

7

Florida Cancer Specialists

Orlando, Florida, United States, 32806

Actively Recruiting

8

University of Chicago

Chicago, Illinois, United States, 60637

Actively Recruiting

9

Hope and Healing Cancer Center

Hinsdale, Illinois, United States, 60521

Active, Not Recruiting

10

Dana-Faber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

11

Nebraska Hematology Oncology

Lincoln, Nebraska, United States, 68506

Active, Not Recruiting

12

Carolina BioOncology Institute

Huntersville, North Carolina, United States, 28078

Active, Not Recruiting

13

Texas Oncology

Tyler, Texas, United States, 75702

Actively Recruiting

14

Virginia Cancer Specialists

Fairfax, Virginia, United States, 22031

Active, Not Recruiting

15

Fred Hutchinson Cancer Center at University of Washington

Seattle, Washington, United States, 98195

Actively Recruiting

16

ICM-Val d'Aurelle

Montpellier, France, 34298

Actively Recruiting

17

CHU de Poitiers

Poitiers, France, 86000

Actively Recruiting

18

Institut de Cancerologie de l'Ouest

Saint-Herblain, France, 44085

Actively Recruiting

19

Gustave Roussy

Villejuif, France, 94805

Actively Recruiting

20

Careggi University Hospital

Florence, Italy, 50314

Actively Recruiting

21

European Institute of Oncology IRCCS

Milan, Italy, 20141

Actively Recruiting

22

Fondazione Policlinico Gemelli, IRCCS

Rome, Italy, 00168

Actively Recruiting

23

Centro Richerche Cliniche di Verona

Verona, Italy, 37134

Actively Recruiting

24

Institute of Oncology/ARENSIA Exploratory Medicine

Chisinau, Moldova, MD-2025

Withdrawn

25

Aresnsia Research Clinic Bucharest

Bucharest, Romania, 22328

Actively Recruiting

26

Aresnsia Research Clinic Cluj-Napoca

Cluj-Napoca, Romania, 400015

Actively Recruiting

27

Centrul de Oncologie Sf. Nectarie

Iași, Romania, 200347

Actively Recruiting

28

Centrul de Oncologie Euroclinic

Iași, Romania, 700106

Actively Recruiting

29

Barcelona IOB Hospital Quironsalud (NEXT)

Barcelona, Spain, 08023

Actively Recruiting

30

Vall d-Hebron Institut d'Oncologia

Barcelona, Spain, 08035

Actively Recruiting

31

Fundacion Jimenez Diaz (START)

Madrid, Spain, 28040

Actively Recruiting

32

Hospital Clinico Universitario de Valencia

Valencia, Spain, 46010

Actively Recruiting

33

University of Birmingham NHS Foundation Trust

Birmingham, United Kingdom, B15 2TH

Actively Recruiting

34

University of Cambridge NHS Foundation Trust

Cambridge, United Kingdom, CB2 0QQ

Actively Recruiting

35

Velindre Cancer Centre

Cardiff, United Kingdom, CF15 7QZ

Actively Recruiting

36

Leeds University Hospitals NHS Trust

Leeds, United Kingdom, LS9 7LP

Actively Recruiting

37

Guy's and St Thomas' Clinical Research Facility

London, United Kingdom, SE1 9RT

Actively Recruiting

38

Imperial Experimental Cancer Medicine Centre

London, United Kingdom, W12 0NN

Actively Recruiting

39

The Christie Hospital

Manchester, United Kingdom, M20 4BX

Actively Recruiting

40

University of Liverpool - Clatterbridge Medical Centre

Metropolitan Borough of Wirral, United Kingdom, CH63 4JY

Actively Recruiting

41

University of Southampton

Southampton, United Kingdom, SO16 6YD

Actively Recruiting

Loading map...

Research Team

I

Ian Hodgson, PhD

CONTACT

R

Rodney Carter, BSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

15

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | DecenTrialz